How much does it cost to bootstrap a gene therapy startup? Not too much if you’re Jim Wilson, per Passage Bio’s $125M IPO filing

Days ago when Deerfield partner Bruce Goldsmith jumped to helm Passage Bio, he cited a few reasons why it’s an “extremely exciting time” to be joining the gene therapy player: IND filings for three lead programs, a data-rich 2021 and an expanding pipeline of experimental drugs for rare, monogenic CNS diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *